Symptoms may include infrequent bowel movements, hard stools, bloating, or difficulty passing stool
By stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying, semaglutide helps lower blood sugar levels, which can positively impact cardiovascular health
In line with evidence accrued in patients with T2D, incretin-based therapies produced a favorable effect on traditional cardiovascular risk factors, such as lipids and blood pressure, and even reduced the risk of major cardiovascular events and heart failure-related events in individuals with obesity, as recently demonstrated for the first time in the SELECT trial with semaglutide 2.4 mg once-weekly
It is important to distinguish between a documented adverse drug reaction and symptoms that may occur coincidentally or through indirect mechanisms during treatment with any medication